Abstract
Background
Cystatin C (cysC) is said to be an ideal marker for glomerular filtration rate (GFR), independent of external factors such as age, nutrition and inflammation. The authors compared the accuracy and precision of cysC-based and creatinine (Cr)-based GFR estimates using Cr51-EDTA GFR method as a reference.
Methods
Serum concentrations of cysC and Cr were measured in adults over 17 yr (n=170) and children below 17 yr (n=79) who had had GFR estimated by Cr51-EDTA method. CysC-based GFR was estimated by the formula of Thierry [CysC-based GFR estimates (mL/min/1.73 m2)=78×(1/cysC, in mg/L)+4] and Cr-based GFR by the formula of modified Modification of Diet in Renal Disease [MDRD II, Cr-based GFR estimates (mL/min/1.73 m2)=186×(Scr)-1.154×(Age)-0.203×0.742 (for a female patient)×1.212 (for a black patient).
Results
In comparison with Cr51-EDTA GFR, in children below 17 yr, the bias±standard deviation (SD) of cysC-based and Cr-based GFR estimates were 7.5±6.1 and 106.5±98.2, respectively, in the range of below 90 of Cr51-EDTA GFR (mL/min/1.73 m2), and 33.7±33.0 and 174.4±18.8 in the range of over 90. In adults over 17 yr, the respective figures were 13.1±11.0 and 17.4±29.8 in below 90, and 21.2±20.1 and 83.6±108.8 in over 90 of Cr51-EDTA GFR.
References
1. Lamb E, Newman DJ, Price CP. Kidney function tests. Burtis CA, Ashwood ER, Bruns ED, editors. eds.Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed.Philadelphia: Elsevier Saunders;2006. p. 818–26.
2. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139:137–47.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(S1):S1–266.
4. Le Bricon T, Thervet E, Froissart M, Benlakehal M, Bousquet B, Legendre C, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem. 2000; 46:1206–7.
5. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41:1–12.
6. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004; 41:467–550.
7. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47:312–8.
8. Cataldi L, Mussap M, Bertelli L, Ruzzante N, Fanos V, Plebani M. Cystatin C in healthy women at term pregnancy and in their infant newborns?: relationship between maternal and neonatal serum levels and reference values. Am J Perinatal. 1999; 16:287–95.
9. Fischbach M, Graff V, Terzic J, Bergere V, Oudet M, Hamel G. Impact of age on reference values for serum concentration of cystatin C in children. Pediatr Nephrol. 2002; 17:104–6.
10. Norlund L, Fex G, Lanke J, Von Schenck H, Nilsson JE, Leksell H, et al. Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2-microglo-bulin/cystain C-ratio. Scand J Clin Lab Invest. 1997; 57:463–70.
11. Finney H, Newman DJ, Price CP. Adult reference ranges serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000; 37:49–59.
12. Erlandsen EJ, Randers E, Kristensen JH. Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med. 1998; 36:393–7.
13. Uhlmann EJ, Hock KG, Issitt C, Sneeringer MR, Cervelli DR, Gorman RT, et al. Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. Clin Chem. 2001; 47:2031–3.
14. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67:2089–100.
15. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003; 338:87–90.
16. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction? Clin Chem. 2003; 49:1558–9.
17. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003; 63:1944–7.
18. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001; 47:2055–9.
19. Tokyol C, Koken T, Demirbas M, Dilek FH, Yorukoglu K, Mungan U, et al. Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori. 2006; 92:230–5.
20. Saleh Y, Sebzda T, Warwas M, Kopec W, Ziolkowska J, Siewinski M. Expression of cystatin C in clinical human colorectal cancer tissues. J Exp Ther Oncol. 2005; 5:49–53.
21. Demirtas S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem. 2006; 39:115–8.